The propensity score was constructed from age at the index date (continuous), sex, race, region, number of RMS relapses in the preindex period (0, 1, 2+), prior DMT in the preindex period, RMS disability in the preindex period, Deyo-Charlson comorbidity index (DCCI) in the preindex period (continuous), and Psychiatric Diagnosis Group index in the preindex period (continuous)
We do, however, accept flex spending or health savings cards
Key Takeaways Gradual dose escalation over 20 weeks minimizes gastrointestinal side effects while building therapeutic efficacy Standard monotherapy reaches a maximum maintenance dose of 4.5 mg weekly after systematic increases Combination protocols (CagriSema) pair cagrilintide with semaglutide for enhanced weight management outcomes Clinical trial data demonstrates approximately 10.8% body weight reduction with monotherapy at 32 weeks Proper injection technique and site rotation are essential for optimal absorption and safety Understanding Cagrilintide: What Health Professionals Need to Know Cagrilintide is a long-acting amylin analogue currently being developed by Novo Nordisk for obesity and type 2 diabetes management
If you want to learn more, read our article about the photolysis of B12